North American Bioreactor Market size is estimated to cross USD 8 billion by 2028, according to a latest forecast report by Graphical Research.
Growing demand for vaccines and other biologics has escalated the product use across drug manufacturing and research units. Prominent pharmaceutical and biotechnology companies have expanded the use of bioreactors in their drug development processes. The outbreak of the deadly COVID-19 virus has affected millions of people across North America. More than six million people in the region were affected with the virus in the region. The rapidly increasing number of COVID-19 fueled the requirement for vaccines to reduce the mortality rate, thereby increasing the use of bioreactors in the region.
Owing to various advantages, single use bioreactors are widely used in the pharmaceutical industry. Factors such as increased productivity, reduced cross-contamination, cost-efficiency, and easy disposal of the residues will favor the use of these components. Increasing need for single-use bioprocessing materials has led to numerous mergers, acquisitions, and partnerships. However, concerns about leachable & extractables for single-use bioreactors and stringent government regulations may impede the market growth.
The bacterial cells segment will grow with a CAGR of 13% through 2028. The use of bacterial cells for cultivation has benefited the pharmaceutical and biotechnology industries. Bacterial cells are frequently employed in the healthcare business due to their potential to offer a wide range of industrial applications and to develop cell lines for human therapeutic usage. Moreover, these cells are tough, resistant to shear damage, and can withstand high agitation rates.
In terms of the molecule, the vaccines segment will gain remarkable momentum during the forecast timeline, due to the increased prevalence of chronic illnesses and infectious diseases in North America, together with rising government healthcare spending. According to the Centers for Disease Control and Prevention (CDC), around 15 million people in the U.S. seek medical attention for parasitic and infectious disorders. Over 4 million patients visit emergency rooms and are diagnosed with an infectious condition. Rising infectious illness cases, the market share from vaccines segment will see consistent growth in the region.
Browse detailed statistical insights from the report, “North America Bioreactors Market Forecast 2028 By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Product Type (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By End-use (R&D Organizations, Biopharma Manufacturers, CMOs), Research Report, Country Outlook (U.S. Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
With regards to the end-users, the biopharma manufacturers segment held more than 42% market share in 2021. A increasing need for therapeutics, orphan pharmaceuticals, and other customized medicines will be important growth drivers for the utilization of bioreactors in manufacturing. The production of metabolites and the expansion of downstream activities would increase bioreactor use among biopharma businesses.
Due to rising number of COVID-19 cases and high mortality rate in Canada, there is a rapid increase in the need for the vaccine development in the region. Moreover, rising healthcare expenditure by the government and expanding healthcare facilities will foster bioreactors deployment in the country. Upsurge in number of R&D facilities and academic institutes is projected to create considerable demand for the products.
The bioreactors in North American market research report includes in-depth coverage of the industry with estimates & forecast in terms of volume in Kilotons & revenue in USD Million from 2017 to 2028, for the following segments:
North America Market, By Product Type
North America Market, By Cell
- Mammalian Cells
- Bacterial Cells
- Yeast Cells
North America Market, By Molecule
- Monoclonal Antibodies
- Recombinant Proteins
- Stem Cells
- Gene Therapy
North America Market, By End-use
- Research and Development (R&D) Organizations
- Biopharmaceutical (biopharma) Manufacturers
- Contract Manufacturing Organizations (CMOs)
The above information has been provided for the following countries: